美国全身麻醉剂市场规模、份额、趋势分析报告：按药物、给药途径、最终用途、应用、国家、细分预测，2025-2030 年

美国全身麻醉剂市场的成长与趋势：

根据 Grand View Research, Inc. 的数据，到 2030 年美国全身麻醉剂市场规模预计将达到 20.3 亿美元，2025 年至 2030 年期间的复合年增长率为 2.82%。

这种增长主要得益于外科手术数量的增加。美国麻醉师协会 (ASA) 强调，由于人口老化、慢性病盛行率上升以及手术技术的进步，手术量持续增加。美国疾病管制与预防中心在 2024 年 2 月报告称，约有 1.29 亿美国人患有至少一种主要慢性疾病，例如癌症、心臟病、糖尿病或高血压。慢性病的高发性导致心血管手术和其他手术的数量增加，对有效全身麻醉剂的需求增加。

麻醉技术的进步也是一个重要驱动因素。REMIFENTANIL等超短效麻醉剂技术创新可以更好地控制麻醉深度并缩短恢復时间，从而改善患者的治疗效果并推动市场成长。此外，包括自动化麻醉输送系统在内的先进输送系统和监测技术的发展正在透过提高精度和安全性彻底改变麻醉实践。

监管发展也扮演重要角色。 FDA 的突破性核准途径有助于快速获取新的有效麻醉剂。例如，新型缓释性麻醉剂ZYNRELEF™ 的最新核准表明，监管方面的进步正在支持创新产品的推出。

美国全身麻醉剂市场报告重点

• 基于医药产品，Propofol部门预计将在 2024 年占据市场主导地位，收益占有率达到 25.52%，并且预计在预测期内将以最快的复合年增长率增长。
• 根据给药途径，静脉注射预计将在 2024 年占据最大的收益占有率，预计在预测期内以 3.03% 的复合年增长率增长。
• 根据应用，膝关节关节重建和髋置换术占据市场主导地位，占据了大部分的收益占有率。
• 根据最终用途，医院部门将占据市场主导地位，到 2024 年将获得 67.05% 的显着收益占有率。医院是进行大型手术和需要全身麻醉的复杂医疗程序的主要场所。

目录

第一章调查方法与范围

第 2 章执行摘要

第 3 章美国全身麻醉剂市场变数、趋势与范围

• 市场展望
  • 母市场展望
  • 相关/附随市场展望
• 市场动态
  • 市场推动要素分析
  • 市场限制因素分析
• 美国全身麻醉剂市场分析工具
  • 产业分析-波特五力分析
  • PESTEL 分析

第 4 章美国全身麻醉药物市场：药物评估与趋势分析

• 药品仪表板
• 药物变异分析
• 按药物和收益
• SEVOFLURANE
• Propofol
• Dexmedetomidine
• REMIFENTANIL
• DESFLURANE
• 咪达唑仑
• 其他的

第 5 章美国全身麻醉剂市场：给药途径估计与趋势分析

• 给药途径仪表板
• 给药途径变异性分析
• 按给药途径分類的收益
• 静脉
• 吸入

第六章美国全身麻醉剂市场：最终用途估计与趋势分析

• 最终用途仪表板
• 最终用途变化分析
• 按最终用途分類的收益
• 医院
• 门诊手术中心
• 其他的

第七章美国全身麻醉剂市场：应用估计与趋势分析

• 应用程式仪表板
• 使用波动分析
• 按用途分類的收益
• 心血管手术
• 癌症
• 一般外科
• 膝关节和髋关节置换术
• 其他的

美国8麻醉剂。

• 区域控制面板
• 市场规模、预测趋势分析，2018 年至 2030 年：
  • 美国

第九章 竞争格局

• 公司/竞争对手分类
• 供应商概况
  • 主要经销商及通路伙伴名单
  • Key company market share analysis, 2024
  • Baxter International Inc.
  • AstraZeneca
  • AbbVie Inc.
  • B. Braun Melsungen AG
  • Fresenius SE &Co. KgaA
  • Pfizer
  • Hospira Inc.
  • Aspen Pharmacare Holdings Limited
  • Hikama Pharmaceuticals plc
  • Abbott Laboratories

U.S. General Anesthesia Drugs Market Growth & Trends:

The U.S. general anesthesia drugs market size is projected to reach USD 2.03 billion by 2030, and is anticipated to grow at a CAGR of 2.82% from 2025 to 2030, according to Grand View Research, Inc. The rising number of surgical procedures primarily drives this growth. The American Society of Anesthesiologists (ASA) highlights a consistent increase in surgeries, attributed to an aging population, the growing prevalence of chronic diseases, and advancements in surgical techniques. The CDC reported in February 2024 that approximately 129 million Americans have at least one major chronic disease, such as cancer, heart disease, diabetes, and hypertension. This high prevalence of chronic conditions necessitates numerous cardiovascular and other surgeries, which in turn drives the demand for effective general anesthesia drugs.

Advancements in anesthesia technology are another critical driver. Innovations such as ultra-short-acting anesthetics, like remifentanil, offer improved control over anesthesia depth and faster recovery times, enhancing patient outcomes and driving market growth. Additionally, the development of advanced delivery systems and monitoring technologies, including automated anesthesia delivery systems, has revolutionized anesthesia practices by improving precision and safety.

Regulatory developments also play a significant role. The FDA's expedited approval pathways for breakthrough therapies facilitate quicker access to new and effective anesthetics. For instance, the recent approval of ZYNRELEFTM, a novel extended-release anesthetic, illustrates how regulatory advancements support the introduction of innovative products.

U.S. General Anesthesia Drugs Market Report Highlights:

• Based on drug, the propofol segment dominated the market with a substantial revenue share of 25.52% in 2024 and is also expected to grow at the fastest CAGR during the forecast period, driven by its widespread use as a preferred agent for induction and maintenance of general anesthesia.
• Based on route of administration, the intravenous segment held the largest revenue share in 2024 and is also expected to grow at the fastest CAGR of 3.03% during the forecast period
• Based on application, the knee and hip replacements segment dominated the market, capturing a substantial revenue share.
• Based on end-use, the hospitals segment dominated the market, capturing a substantial revenue share of 67.05% in 2024. Hospitals are the primary settings for major surgeries and complex medical procedures that require general anesthesia.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Drug
  • 1.2.2. Route of Administration
  • 1.2.3. End Use
  • 1.2.4. Application
  • 1.2.5. Regional scope
  • 1.2.6. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Drug Outlook
  • 2.2.2. Route of Administration
  • 2.2.3. End Use
  • 2.2.4. Application
  • 2.2.5. Regional outlook
• 2.3. Competitive Insights

Chapter 3. U.S. General Anesthesia Drugs Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing Volume Of Surgical Procedures
    • 3.2.1.2. Advancements In Anesthesia Technology
    • 3.2.1.3. Regulatory Developments
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Regulatory and Compliance Challenges
    • 3.2.2.2. Adverse Effects and Safety Concerns
• 3.3. U.S. General Anesthesia Drugs Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. U.S. General Anesthesia Drugs Market: Drug Estimates & Trend Analysis

• 4.1. U.S. General Anesthesia Drugs Market: Drug Dashboard
• 4.2. U.S. General Anesthesia Drugs Market: Drug Movement Analysis
• 4.3. U.S. General Anesthesia Drugs Market by Drug, Revenue
• 4.4. Sevoflurane
  • 4.4.1. Sevoflurane market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Propofol
  • 4.5.1. Propofol market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. Dexmedetomidine
  • 4.6.1. Dexmedetomidine market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. Remifentanil
  • 4.7.1. Remifentanil market estimates and forecasts 2018 to 2030 (USD Million)
• 4.8. Desflurane
  • 4.8.1. Desflurane market estimates and forecasts 2018 to 2030 (USD Million)
• 4.9. Midazolam
  • 4.9.1. Midazolam market estimates and forecasts 2018 to 2030 (USD Million)
• 4.10. Others
  • 4.10.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. U.S. General Anesthesia Drugs Market: Route of Administration Estimates & Trend Analysis

• 5.1. U.S. General Anesthesia Drugs Market: Route of Administration Dashboard
• 5.2. U.S. General Anesthesia Drugs Market: Route of Administration Movement Analysis
• 5.3. U.S. General Anesthesia Drugs Market Estimates and Forecasts, By Route of Administration, Revenue (USD Million)
• 5.4. Intravenous
  • 5.4.1. Intravenous market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Inhaled
  • 5.5.1. Inhaled market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. U.S. General Anesthesia Drugs Market: End Use Estimates & Trend Analysis

• 6.1. U.S. General Anesthesia Drugs Market: End Use Dashboard
• 6.2. U.S. General Anesthesia Drugs Market: End Use Movement Analysis
• 6.3. U.S. General Anesthesia Drugs Market Estimates and Forecasts, By End Use, Revenue (USD Million)
• 6.4. Hospitals
  • 6.4.1. Hospitals market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Ambulatory Surgical Centers
  • 6.5.1. Ambulatory Surgical Centers market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Others
  • 6.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. U.S. General Anesthesia Drugs Market: Application Estimates & Trend Analysis

• 7.1. U.S. General Anesthesia Drugs Market: Application Dashboard
• 7.2. U.S. General Anesthesia Drugs Market: Application Movement Analysis
• 7.3. U.S. General Anesthesia Drugs Market Estimates and Forecasts, By Application, Revenue (USD Million)
• 7.4. Heart Surgeries
  • 7.4.1. Heart Surgeries market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. Cancer
  • 7.5.1. Cancer market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. General Surgery
  • 7.6.1. Other market estimates and forecasts 2018 to 2030 (USD Million)
• 7.7. Knee and hip replacements
  • 7.7.1. Other market estimates and forecasts 2018 to 2030 (USD Million)
• 7.8. Other
  • 7.8.1. Other market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. U.S. General Anesthesia Drugs Market: Regional Estimates & Trend Analysis by Drug, Route of Administration, End Use and Application

• 8.1. Regional Dashboard
• 8.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 8.2.1. U.S.
    • 8.2.1.1. Key country dynamics
    • 8.2.1.2. Regulatory framework/ reimbursement structure
    • 8.2.1.3. Competitive scenario
    • 8.2.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Company/Competition Categorization
• 9.2. Vendor Landscape
  • 9.2.1. List of key distributors and channel partners
  • 9.2.2. Key company market share analysis, 2024
  • 9.2.3. Baxter International Inc.
    • 9.2.3.1. Company overview
    • 9.2.3.2. Financial performance
    • 9.2.3.3. Drug benchmarking
    • 9.2.3.4. Strategic initiatives
  • 9.2.4. AstraZeneca
    • 9.2.4.1. Company overview
    • 9.2.4.2. Financial performance
    • 9.2.4.3. Drug benchmarking
    • 9.2.4.4. Strategic initiatives
  • 9.2.5. AbbVie Inc.
    • 9.2.5.1. Company overview
    • 9.2.5.2. Financial performance
    • 9.2.5.3. Drug benchmarking
    • 9.2.5.4. Strategic initiatives
  • 9.2.6. B. Braun Melsungen AG
    • 9.2.6.1. Company overview
    • 9.2.6.2. Financial performance
    • 9.2.6.3. Drug benchmarking
    • 9.2.6.4. Strategic initiatives
  • 9.2.7. Fresenius SE & Co. KgaA
    • 9.2.7.1. Company overview
    • 9.2.7.2. Financial performance
    • 9.2.7.3. Drug benchmarking
    • 9.2.7.4. Strategic initiatives
  • 9.2.8. Pfizer
    • 9.2.8.1. Company overview
    • 9.2.8.2. Financial performance
    • 9.2.8.3. Drug benchmarking
    • 9.2.8.4. Strategic initiatives
  • 9.2.9. Hospira Inc.
    • 9.2.9.1. Company overview
    • 9.2.9.2. Financial performance
    • 9.2.9.3. Drug benchmarking
    • 9.2.9.4. Strategic initiatives
  • 9.2.10. Aspen Pharmacare Holdings Limited
    • 9.2.10.1. Company overview
    • 9.2.10.2. Financial performance
    • 9.2.10.3. Drug benchmarking
    • 9.2.10.4. Strategic initiatives
  • 9.2.11. Hikama Pharmaceuticals plc
    • 9.2.11.1. Company overview
    • 9.2.11.2. Financial performance
    • 9.2.11.3. Drug benchmarking
    • 9.2.11.4. Strategic initiatives
  • 9.2.12. Abbott Laboratories
    • 9.2.12.1. Company overview
    • 9.2.12.2. Financial performance
    • 9.2.12.3. Drug benchmarking
    • 9.2.12.4. Strategic initiatives

List of Tables

• Table 1 List Of Abbreviation
• Table 2 U.S. General Anesthesia Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 3 U.S. General Anesthesia Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 4 U.S. General Anesthesia Drugs Market, By End Use, 2018 - 2030 (USD Million)
• Table 5 U.S. General Anesthesia Drugs Market, Application, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Primary interviews in North America
• Fig. 5 Market research approaches
• Fig. 6 Value-chain-based sizing & forecasting
• Fig. 7 QFD modeling for market share assessment
• Fig. 8 Market formulation & validation
• Fig. 9 U.S. General Anesthesia Drugs Market: Market Outlook
• Fig. 10 Colorectal Surgery Competitive Insights
• Fig. 11 Parent market outlook
• Fig. 12 Related/ancillary market outlook
• Fig. 13 U.S. General Anesthesia Drugs Market Driver Impact
• Fig. 14 U.S. General Anesthesia Drugs Market Restraint Impact
• Fig. 15 U.S. General Anesthesia Drugs Market Strategic Initiatives Analysis
• Fig. 16 U.S. General Anesthesia Drugs Market: Drug Movement Analysis
• Fig. 17 U.S. General Anesthesia Drugs Market: Drug Outlook And Key Takeaways
• Fig. 18 Sevoflurane market estimates and forecast, 2018 - 2030
• Fig. 19 Propofol market estimates and forecast, 2018 - 2030
• Fig. 20 Dexmedetomidine market estimates and forecast, 2018 - 2030
• Fig. 21 Remifentanil market estimates and forecast, 2018 - 2030
• Fig. 22 Desflurane market estimates and forecast, 2018 - 2030
• Fig. 23 Midazolam market estimates and forecast, 2018 - 2030
• Fig. 24 Others market estimates and forecast, 2018 - 2030
• Fig. 25 U.S. General Anesthesia Drugs Market: Route of Administration Movement Analysis
• Fig. 26 U.S. General Anesthesia Drugs Market: Route of Administration Outlook And Key Takeaways
• Fig. 27 Intravenous market estimates and forecast, 2018 - 2030
• Fig. 28 Inhaled market estimates and forecast, 2018 - 2030
• Fig. 29 U.S. General Anesthesia Drugs Market: End Use Movement Analysis
• Fig. 30 U.S. General Anesthesia Drugs Market: End Use Outlook And Key Takeaways
• Fig. 31 Hospitals market estimates and forecast, 2018 - 2030
• Fig. 32 Ambulatory Surgical Centers market estimates and forecast, 2018 - 2030
• Fig. 33 Others market estimates and forecast, 2018 - 2030
• Fig. 34 U.S. General Anesthesia Drugs Market: Application Movement Analysis
• Fig. 35 U.S. General Anesthesia Drugs Market: Application Outlook And Key Takeaways
• Fig. 36 Heart Surgeries market estimates and forecast, 2018 - 2030
• Fig. 37 Cancer market estimates and forecast, 2018 - 2030
• Fig. 38 General Surgery market estimates and forecast, 2018 - 2030
• Fig. 39 Knee and hip replacements market estimates and forecast, 2018 - 2030
• Fig. 40 Other market estimates and forecast, 2018 - 2030
• Fig. 41 Market share of key market players- U.S. General Anesthesia Drugs Market